New drugs for HDL-C disorders: The beginning

My Ngan Duong, Stephen J. Nicholls

Research output: Contribution to journalArticle

2 Citations (Scopus)


For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.

Number of pages5
JournalCurrent Medicinal Chemistry
Issue number25
Publication statusPublished - 1 Jan 2014


  • Atherosclerosis
  • Cardiovascular disease
  • HDL
  • Lipids
  • Risk factors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this